<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02393248</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 54828-101</org_study_id>
    <nct_id>NCT02393248</nct_id>
  </id_info>
  <brief_title>Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies</brief_title>
  <official_title>A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study will be to evaluate the safety, tolerability, and pharmacological
      activity of INCB054828 in subjects with advanced malignancies. This study will have three
      parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the maximum tolerated dose of INCB054828 as a monotherapy and in combination as measured by the number of participants with adverse events</measure>
    <time_frame>from baseline through 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the pharmacodynamics of INCB054828 as a monotherapy and in combination as indicated by serum phosphorus level</measure>
    <time_frame>up to 30 days (+ 5 days) follow-up visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy as assessed by Overall Response Rate (ORR) of INCB054828 as monotherapy and in combination in subjects with measurable disease</measure>
    <time_frame>Day 15 of every third cycle (± 2 days) while subjects are on study</time_frame>
    <description>Tumor response rates in those subjects with measurable disease as determined by investigator assessment of response using RECIST (Response Evaluation Criteria in Solid Tumor) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) during the dosing interval and Cmin of INCB054828 as monotherapy and in combination</measure>
    <time_frame>Cycle 1 Day 1, Day 2, Day 8 and Day 15</time_frame>
    <description>The pharmacokinetic (PK) parameters of Cmax and Cmin will be calculated from the blood plasma concentrations of INCB054828 using standard noncompartmental PK methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum observed plasma concentration (Cmin) during the dosing interval of INCB054828 as monotherapy and in combination</measure>
    <time_frame>Cycle 1 Day 1, Day 2, Day 8 and Day 15</time_frame>
    <description>The pharmacokinetic (PK) parameters of Cmax and Cmin will be calculated from the blood plasma concentrations of INCB054828 using standard noncompartmental PK methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax) of INCB054828 as monotherapy and in combination</measure>
    <time_frame>Cycle 1 Day 1, Day 2, Day 8 and Day 15</time_frame>
    <description>The PK parameter of Tmax will be calculated from the blood plasma concentrations of INCB054828 using standard noncompartmental PK methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the single-dose plasma concentration-time curve (AUC0-t) of INCB054828 as monotherapy and in combination</measure>
    <time_frame>Cycle 1 Day 1, Day 2, Day 8 and Day 15</time_frame>
    <description>Area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration, calculated by the linear trapezoidal rule for increasing concentrations and the log trapezoidal rule for decreasing concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral dose clearance (Cl/F) of INCB054828 as monotherapy and in combination</measure>
    <time_frame>Cycle 1 Day 1, Day 2, Day 8 and Day 15</time_frame>
    <description>The PK parameter of Cl/F will be calculated from the blood plasma concentrations of INCB054828 using standard noncompartmental PK methods.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Solid Tumor</condition>
  <condition>Gastric Cancer</condition>
  <condition>UC (Urothelial Cancer)</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Multiple Myeloma</condition>
  <condition>MPN (Myeloproliferative Neoplasms)</condition>
  <condition>Breast Cancer</condition>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label dose escalation with an accelerated titration design based on observing each dose level for a period of 21 days.
Dose Expansion
Combination therapy:
Gemcitabine + Cisplatin + INCB054828
Pembrolizumab + INCB054828
Docetaxel + INCB054828
Trastuzumab + INCB054828</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB054828</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine+Cisplatin</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects, age 18 years or older on day of signing consent

          2. Part 1: Any advanced solid tumor malignancy; Part 2: Subjects with squamous non-small
             cell lung cancer, cholangiocarcinoma/gastric cancer, urothelial cancer,
             breast/endometrial cancer, multiple myeloma, or MPNs that have a tumor or malignancy
             that has been evaluated and confirmed to harbor genetic alterations in FGF or FGFR
             genes. A subject's fibroblast growth factor (FGF) or fibroblast growth factor receptor
             (FGFR) alteration may be based on local or central laboratory results. Part 3: Dose
             finding: subjects with solid tumor malignancies who qualify for combo therapy;
             dose-expansion: FGF/FGFR+ subjects qualified to receive combo therapy

          3. Has progressed after prior therapy and there is no further effective standard
             anticancer therapy available (including subject refuses or is intolerant)

          4. Life expectancy &gt; 12 weeks

          5. Eastern Cooperative Oncology Group (ECOG) performance status:

               -  Part 1: 0 or 1

               -  Part 2 and 3: 0, 1, or 2

        Exclusion Criteria:

          1. Treatment with other investigational study drug for any indication for any reason, or
             receipt of anticancer medications within 21 days or 5 half-lives before first dose of
             study drug

          2. Prior receipt of a selective FGFR inhibitor

          3. History of a calcium/phosphate homeostasis disorder

          4. History and/or current evidence of ectopic mineralization/calcification

          5. Current evidence of corneal disorder/keratopathy

          6. Has a history or presence of inadequate liver, renal, hematopoietic and/or cardiac
             function parameters outside protocol-defined range

          7. Prior radiotherapy within 2 weeks of study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Féliz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Call Center</last_name>
    <phone>1-855-463-3463</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University - Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hematology - Oncology Associates of Treasure Coast</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Signal Point Clinical Research Center</name>
      <address>
        <city>Middletown</city>
        <state>Ohio</state>
        <zip>45042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologisk Klinik Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alterations in FGF or FGFR</keyword>
  <keyword>squamous non-small cell lung cancer</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>urothelial cancer</keyword>
  <keyword>endometrial cancer</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>MPN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

